Genotoxic impurities: From structural alerts to qualification

Organic Process Research and Development

Volumn 14, Issue 4, 2010, Pages 960-976

  Snodin, David J ^a  

^a Xiphora Biopharma Consulting   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; AROMATIC AMINES; BIOLOGICAL ACTIVITIES; DRUG SUBSTANCES; GENOTOXIC IMPURITIES; GENOTOXICITIES; IN-SILICO; LOW COSTS; REPRESENTATIVE COMPOUND; REVERSE MUTATION; STARTING MATERIALS;

ALDEHYDES; AMINES; CHEMICAL REACTIONS; IMPURITIES;

DRUG PRODUCTS;

EID: 77955349319     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/op100118e     Document Type: Article

References (163)

1. Ashby, J.; Tennant, R. W. Definitive Relationships among Chemical Structure, Carcinogenicity and Mutagenicity for 301 Chemicals Tested by the U.S. NTP Mutat. Res. 1991, 257, 229-306
2. EU Guideline of Limits of Genotoxic Impurities, http://www.ema.europa.eu/ pdfs/human/swp/519902en.pdf.
3. Q&A supplement, http://www.ema.europa.eu/pdfs/human/swp/43199407en. pdf.
4. Safety Evaluation of Certain Food Additives and Contaminants, WHO Food Additives Series 40; http://www.inchem.org/documents/jecfa/jecmono/v040je17.htm.
5. Bossa, C.; Worth, A.; Netzeva, T.; Jeliazkova-Nikolova, N.; Benigni, R. A New Model for Predicting Mutagens/Carcinogens Implemented in Toxtree v1.4; http://www.scarlet-project.eu/posters/Bossa-C-scarlet.pdf.
6. Sawatari, K.; Nakanishi, Y.; Matsushima, T. Relationships between Chemical Structures and Mutagenicity: A Preliminary Survey for a Database of Mutagenicity Test Results of New Work Place Chemicals Ind. Health 2001, 39, 341-345
7. Sakano, K.; Oikawa, S.; Hiraku, Y.; Kawanishi, S. Mechanism of Metal-Mediated DNA Damage Induced by a Metabolite of Carcinogenic Acetamide Chem. Biol. Interact. 2004, 149, 52-59
8. Chemical Carcinogenesis Research Information System (CCRIS); http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?CCRIS.
9. Dobo, K. L.; Greene, N.; Cyr, M. O.; Caron, S.; Ku, W. W. The Application of Structure-Based Assessment to Support Safety and Chemistry Diligence to Manage Genotoxic Impurities in Active Pharmaceutical Ingredients during Drug Development Regul. Toxicol. Pharmacol. 2006, 44, 282-293
10. Concise International Chemical Assessment Document 74: 2-Butenal: http://www.inchem.org/documents/cicads/cicads/cicad74.pdf.
11. Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals, No 471, Bacterial Reverse Mutation Test: http://www.oecd.org/dataoecd/18/31/1948418.pdf.
12. Gold, L. S.; Slone, T. H.; Stern, B. R.; Bernstein, L. Comparison of Target Organs of Carcinogenicity for Mutagenic and Non-mutagenic Chemicals Mutat. Res. 1993, 286, 75-100
13. Hengstler, J. G.; Bogdanffy, M. S.; Bolt, H. M.; Oesch, F. Challenging Dogma: Thresholds for Genotoxic Carcinogens? The Case of Vinyl Acetate Annu. Rev. Pharmacol. Toxicol. 2003, 43, 485-520
14. Gaylor, D. W. Are Tumor Incidence Rates from Chronic Bioassays Telling Us What We Need to Know about Carcinogens? Regul. Toxicol. Pharmacol. 2005, 41, 128-133
15. Counts, J. L.; Goodman, J. I. Principles Underlying Dose Selection for, and Extrapolation from, the Carcinogen Bioassay: Dose Influences Mechanism Regul. Toxicol. Pharmacol. 1995, 21, 418-421
16. Knight, A.; Bailey, J.; Balcombe, J. Animal Carcinogenicity Studies: 2. Obstacles to Extrapolation of Data to Humans ATLA, Altern. Lab Anim. 2006, 34, 29-38
17. Carcinogenic Potency Database: Aniline; http://potency.berkeley.edu/ chempages/aniline.html.
18. Carcinogenic Potency Database: Aniline Hydrochloride; http://potency.berkeley.edu/chempages/aniline.HCl.html.
19. Bailey, G. S.; Reddy, A. P.; Pereira, C. B.; Harttig, U.; Baird, W.; Spitsbergen, J. M.; Hendricks, J. D.; Orner, G. A.; Williams, D. E.; Swenberg, J. A. Nonlinear Cancer Response at Ultralow Dose: a 40800-Animal ED(001) Tumor and Biomarker Study Chem. Res. Toxicol. 2009, 22, 1264-1276
20. Sawyer, C.; Peto, R.; Bernstein, L.; Pike, M. C. Calculation of Carcinogenic Potency from Long-Term Animal Carcinogenesis Experiments Biometrics 1984, 40, 27-40
21. Carcinogenic Potency Database; http://toxnet.nlm.nih.gov/cgi-bin/sis/ htmlgen?CPDB.htm.
22. Kroes, R.; Renwick, A. G.; Cheeseman, M.; Kleiner, J.; Mangelsdorf, I.; Piersma, A.; Schilter, B.; Schlatter, J.; van Schothorst, F.; Vos, J. G.; Wurtzen, G. Structure-Based Thresholds of Toxicological Concern (TTC):Guidance for Application to Substances Present at Low Levels in the Diet Food Chem. Toxicol. 2004, 42, 65-83
23. Cheeseman, M. A.; Machuga, E. J.; Bailey, A. B. A Tiered Approach to Threshold of Regulation Food Chem. Toxicol. 1999, 37, 387-412
24. Mullera, L.; Gocke, E.; Lave, T.; Pfister, T. Ethyl Methanesulfonate Toxicity in Viracept: A Comprehensive Human Risk Assessment Based on Threshold Data for Genotoxicity Toxicol. Lett. 2009, 190, 317-29
25. Snyder, R. D. An Update on the Genotoxicity and Carcinogenicity of Marketed Pharmaceuticals with Reference to in Silico Predictivity Environ. Mol. Mutagen. 2009, 50, 435-450
26. Kirkland, D.; Aardema, M.; Henderson, L.; Mullera, L. Evaluation of the Ability of a Battery of Three in Vitro Genotoxicity Tests to Discriminate Rodent Carcinogens and Non-Carcinogens I. Sensitivity, Specificity and Relative Predictivity Mutat. Res. 2005, 584, 1-256
27. Caldwell, J. Perspective on the Usefulness of the Mouse Lymphoma Assay As an Indicator of a Genotoxic Carcinogen: Ten Compounds Which Are Positive in the Mouse Lymphoma Assay but Are Not Genotoxic Carcinogens Teratog. Carcinog. Mutagen. 1993, 13, 185-190
28. Potentially Genotoxic Impurities and European Pharmacopoeia Monographs on Substances for Human Use; http://www.edqm.eu/medias/fichiers/NEW-Potentialy- genotoxic-impurities-PhEur-monographs.pdf.
29. Mullera, L.; Gocke, E. Considerations Regarding a Permitted Daily Exposure Calculation for Ethyl Methanesulfonate Toxicol. Lett. 2009, 190, 330-2
30. Carcinogenic Potency Database: 1-Nitrosohydantoin; http://potency. berkeley.edu/chempages/1-nitrosohydantoin.html.
31. Pierson, D. A.; Olsen, B. A.; Robbins, D. K.; DeVries, K. M.; Varie, D. L. Approaches to Assessment, Testing Decisions, and Analytical Determination of Genotoxic Impurities in Drug Substances Org. Process Res. Dev. 2009, 13, 285-291
32. Ganapthy, M. Control of Genotoxic Impurities and the Regulatory Impact of This: A Case Study; AAPS Annual Meeting, 12th November 2009; http://mediaserver.aapspharmaceutica.com/meetings/09AM/Slides/11.12.09-Thu/ 409%20AB/1330/Ganapathy%20Mohan.pdf.
33. Liu, D. Q.; Sun, M.; Kord, A. S. Recent Advances in Trace Analysis of Pharmaceutical Genotoxic Impurities J. Pharm. Biomed. Anal. 2010, 51, 999-1014
34. Sun, M.; Bai, L.; Terfloth, G. J.; Liu, D. Q.; Kord, A. S. Matrix Deactivation: a General Approach to Improve Stability of Unstable and Reactive Pharmaceutical Genotoxic Impurities for Trace Analysis J. Pharm. Biomed. Anal. 2010, 52, 30-36
35. Bai, L.; Sun, M.; An, J.; Liu, D. Q.; Chen, T. K.; Kord, A. S. Enhancing the Detection Sensitivity of Trace Analysis of Pharmaceutical Genotoxic Impurities by Chemical Derivatization and Coordination Ion Spray-Mass Spectrometry J. Chromatogr., A 2010, 1217, 302-306
36. Borg, J. J.; Robert, J.-L.; Wade, G.; Aislaitner, G.; Pirozynski, M.; Abadie, E.; Salmonson, T.; Vella Bonanno, P. Where is industry getting it wrong? A Review of Quality Concerns Raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products J. Pharm. Pharm. Sci. 2009, 12, 181-198
37. Arxxant withdrawal assessment report; http://www.ema.europa.eu/humandocs/ PDFs/EPAR/arxxant/15096407en.pdf.
38. Factive withdrawal assessment report; http://www.ema.europa.eu/humandocs/ PDFs/EPAR/factive/Factive-WEPAR.pdf.
39. Yang, Q.; Haney, B. P.; Vaux, A.; Riley, D. A.; Heidrich, L.; He, P.; Mason, P.; Tehim, A.; Fisher, L. E.; Maag, H.; Anderson, N. G. Controlling the Genotoxins Ethyl Chloride and Methyl Chloride Formed During the Preparation of Amine Hydrochloride Salts from Solutions of Ethanol and Methanol Org. Process Res. Dev. 2009, 13, 786-791
40. Schuile, A.; Ates, C.; Palacio, M.; Stofferis, J.; Delatinne, J.-P.; Martin, B.; Lloyd, S. Monitoring and Control of Genotoxic Impurity Acetamide in the Synthesis of Zaurategrast Sulfate. Org. Process Res. Dev. 2010. DOI: 10.1021/op900330e.
41. Carcinogenic Potency Database: Acetamide; http://potency.berkeley.edu/ chempages/ACETAMIDE.html.
42. Friscia, O.; Pulci, R.; Fassio, F.; Comelli, R. Chemical Reagents As Potential Impurities of Pharmaceutical Products: Investigations on Their Genotoxic Activity J. Environ. Pathol. Toxicol. Oncol. 1994, 13, 89-110
43. Amberg, A.; Braun, K.; Czich, A.; Kauffmann, H.-M.; Spirkl, H.-P.; Stammberger, I.; Troschau, G. Positive Genotoxicity Results Due to the Formation of Genotoxic Reaction-Products of the Solvent DMSO with Carboxylic/Sulfonic Acid Halides. Toxicological Sciences, The Toxicologist Supplement 2007, Abstract No 1661.
44. Guideline on the Specification Limits for Residues of Metal Catalysts or Metal Reagents; http://www.ema.europa.eu/pdfs/human/swp/444600enfin.pdf.
45. Specifications for Class 1 and Class 2 Residual Solvents in Active Substances; http://www.ema.europa.eu/pdfs/human/qwp/045003en.pdf.
46. Impurities. Residual Solvents. ICH Topic Q3C (R3); http://www.emea. europa.eu/pdfs/human/ich/028395en.pdf.
47. Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches; http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079235.pdf.
48. Mullera, L.; Mauthe, R. J.; Riley, C. M.; Andino, M. M.; Beels, C.; De Antonis, D.; DeGeorge, J.; De Knaep, A. G.; Ellison, D.; Fagerland, J. A.; Frank, R.; Fritschel, B.; Galloway, S.; Harpur, E.; Humfrey, C. D. N.; Jacks, A. S.; Jagota, N.; Mackinnon, J.; Mohan, G.; Ness, D. K.; O'Donovan, M. R.; Smith, M. D.; Vudathala, G.; Yotti, L. A Rationale for Determining, Testing, and Controlling Specific Impurities in Pharmaceuticals That Possess Potential for Genotoxicity Regul. Toxicol. Pharmacol. 2006, 44, 198-211
49. Manson, M. M. Epoxides - Is There a Human Health Problem Br. J. Ind. Med. 1980, 37, 317-336
50. von der Hude, W.; Seelbach, A.; Basler, A. Epoxides: Comparison of the Induction of SOS Repair in Escherichia coli PQ37 and the Bacterial Mutagenicity in the Ames Test Mutat. Res. 1990, 231, 205-218
51. Wade, D. R.; Airy, S. C.; Sinsheimer, J. E. Mutagenicity of Aliphatic Epoxides Mutat. Res. 1978, 58, 217-223
52. Glatt, H.; Jung, R.; Oesch, F. Bacterial Mutagenicity Investigation of Epoxides: Drugs, Drug Metabolites, Steroids and Pesticides Mutat. Res. 1983, 111, 99-118
53. Epoxides (as flavouring agents); http://www.inchem.org/documents/jecfa/ jecmono/v56je12.pdf.
54. Dunkelberg, H. Carcinogenicity of Ethylene Oxide and 1,2-Propylene Oxide upon Intragastric Administration to Rats Br. J. Cancer 1982, 46, 924-933
55. Albertini, R. J.; Sweeney, L. M. Propylene Oxide: Genotoxicity Profile of a Rodent Nasal Carcinogen Crit. Rev. Toxicol. 2007, 37, 489-520
56. Hengstler, J. G.; Bogdanffy, M. S.; Bolt, H. M.; Oesch, F. Challenging Dogma: Thresholds for Genotoxic Carcinogens? The Case of Vinyl Acetate Annu. Rev. Pharmacol. Toxicol. 2003, 43, 485-520
57. Morisseau, C.; Hammock, B. D. Epoxide Hydrolases: Mechanisms, Inhibitor Designs, and Biological Roles Annu. Rev. Pharmacol. Toxicol. 2005, 45, 311-333
58. Newman, J. W.; Morisseau, C.; Hammock, B. D. Epoxide Hydrolases: Their Roles and Interactions with Lipid Metabolism Prog. Lipid Res. 2005, 44, 1-51
59. Arand, M.; Cronin, A.; Adamska, M.; Oesch, F. Epoxide Hydrolases: Structure, Function, Mechanism, and Assay Methods Enzymol. 2005, 400, 569-588
60. Oesch, F.; Herrero, M. E.; Hengstler, J. G.; Lohmann, M.; Arand, M. Metabolic Detoxification: Implications for Thresholds Toxicol Pathol. 2000, 28, 382-387
61. Henderson, R. F. Species Differences in the Metabolism of Olefins: Implications for Risk Assessment Chem. Biol. Interact. 2001, 135-136, 53-64
62. Guenthner, T. M.; Luo, G. Investigation of the Role of the 2C,3C-Epoxidation Pathway in the Bioactivation and Genotoxicity of Dietary Allylbenzene Analogs Toxicology 2001, 160, 47-58
63. Seidegard, J.; Ekstrom, G. The Role of Human Glutathione Transferases and Epoxide Hydrolases in the Metabolism of Xenobiotics Environ. Health Perspect. 1997, 105 (Suppl. 4) 791-799
64. Testa, B.; Kramer, S. D. The Biochemistry of Drug Metabolism: An Introduction: Part 4. Reactions of Conjugation and Their Enzymes Chem. Biodivers. 2008, 5, 2171-2336
65. Shimada, T. Xenobiotic-Metabolizing Enzymes Involved in Activation and Detoxification of Carcinogenic Polycyclic Aromatic Hydrocarbons Drug Metab. Pharmacokinet. 2006, 21, 257-276
66. Madden, S.; Maggs, J. L.; Park, B. K. Bioactivation of Carbamazepine in the Rat in Vivo. Evidence for the Formation of Reactive Arene Oxide(s) Drug Metab. Dispos. 1996, 24, 469-479
67. Roy, D.; Snodgrass, W. R. Phenytoin Metabolic Activation: Role of Cytochrome P-450, Glutathione, Age, and Sex in Rats and Mice Res. Commun. Chem. Pathol. Pharmacol. 1988, 59, 173-190
68. Maggs, J. L.; Naisbitt, D. J.; Tettey, J. N. A.; Pirmohamed, M.; Park, B. K. Metabolism of Lamotrigine to a Reactive Arene Oxide Intermediate Chem. Res. Toxicol. 2000, 13, 1075-1081
69. Wen, B.; Ma, L.; Zhu, M. Bioactivation of the Tricyclic Antidepressant Amitriptyline and Its Metabolite Nortriptyline to Arene Oxide Intermediates in Human Liver Microsomes and Recombinant P450s Chem. Biol. Interact. 2008, 173, 59-67
70. Yan, Z.; Li, J.; Huebert, N.; Caldwell, G. W.; Du, Y.; Zhong, H. Detection of a Novel Reactive Metabolite of Diclofenac: Evidence for CYP2C9-Mediated Bioactivation via Arene Oxides Drug Metab. Dispos. 2005, 33, 706-713
71. WHO Food Additive Series 50, Aliphatic Secondary Alcohols, Ketones and Related Esters; http://www.inchem.org/documents/jecfa/jecmono/v50je15.htm.
72. Deininger, C.; Eder, E.; Neudecker, T.; Hoffman, C. Mutagenicity and Genotoxicity of Ethylvinyl Ketone in Bacterial Tests J. Appl. Toxicol. 1990, 10, 167-171
73. Obach, R. S.; Dobo, K. L. Comparison of Metabolite Profiles Generated in Aroclor-Induced Rat Liver and Human Liver Subcellular Fractions: Considerations for in Vitro Genotoxicity Hazard Assessment Environ. Mol. Mutagen. 2008, 49, 631-641
74. International Programme on Chemical Safety, Environmental Health Criteria 68, Hydrazine; http://www.inchem.org/documents/ehc/ehc/ehc68.htm.
75. Agency for Toxic Substances and Disease Registry, Toxicological Profile for Hydrazines; http://www.atsdr.cdc.gov/toxprofiles/tp100.pdf.
76. International Agency for Research on Cancer, Hydrazine; http://www.inchem.org/documents/iarc/vol71/037-hydraz.html; http://monographs. iarc.fr/ENG/Monographs/vol71/mono71-43.pdf.
77. Environmental Protection Agency, Integrated Risk Information System, Hydrazine/Hydrazine Sulfate; http://www.epa.gov/iris/subst/0352.htm.
78. Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, Hydrazine/Hydrazine Sulfate; http://oehha.ca.gov/prop65/pdf/2009FebruaryStat.pdf.
79. Chemicals Evaluation and Research Institute Japan, Hazard Assessment Report-Hydrazine; http://www.cerij.or.jp/ceri-en/hazard-assessment-report/pdf/ en-302-01-2.pdf.
80. Huq, F. Molecular modelling analysis of the metabolism of hydrazine J. Pharmacol. Toxicol. 2006, 1, 485-489
81. N -Methylhydrazine, Evaluation of the Carcinogenicity and Genotoxicity, Nr 2002/07OSH; Dutch Expert Committee on Occupational Standards: The Hague, 2002; http://www.gezondheidsraad.nl/sites/default/files/02@07OSH.PDF.
82. Summary of Product Characteristics, Apresoline Tablets 25 mg; http://www.medicines.org.uk/EMC/medicine/10820/SPC/Apresoline+Tablets+25+mg/.
83. Chung, K.-T.; Kirkovsky, L.; Kirkovsky, A.; Purcell, W. P. Review of Mutagenicity of Monocyclic Aromatic Amines: Quantitative Structure-Activity Relationships Mutat. Res. 1997, 387, 1-16
84. Bartsch, H. Metabolic Activation of Aromatic Amines and Azo Dyes IARC Sci. Publ. 1981, 13-30
85. Gorrod, J. W.; Manson, D. The Metabolism of Aromatic Amines Xenobiotica 1986, 16, 933-955
86. Williams, G. M. DNA Reactive and Epigenetic Carcinogens Exp. Toxicol. Pathol. 1992, 44, 457-463
87. Kerdar, R. S.; Dehner, D.; Wild, D. Reactivity and Genotoxicity of Arylnitrenium Ions in Bacterial and Mammalian Cells Toxicol. Lett. 1993, 67, 73-85
88. Environmental Health Criteria 230: Nitrobenzene: http://www.inchem.org/ documents/ehc/ehc/ehc230.htm.
89. Organisation for Economic Co-operation and Development (OECD) Screening Information Data Sets (SIDS); 2,4-dinitrotoluene: http://www.inchem.org/ documents/sids/sids/121142.html.
90. Suter, W.; Hartmann, A.; Poetter, F.; Sagelsdorff, P.; Hoffmann, P.; Martus, H.-J. Genotoxicity Assessment of the Antiepileptic Drug AMP397, an Ames-Positive Aromatic Nitro Compound Mutat. Res. 2002, 518, 181-194
91. Colvin, M. E.; Hatch, F. T.; Felton, J. S. Chemical and Biological Factors Affecting Mutagen Potency Mutat. Res. 1998, 400, 479-492
92. Ford, G. P.; Herman, P. S. Relative Stabilities of Nitrenium Ions Derived from Polycyclic Aromatic Amines. Relationship to Mutagenicity Chem. Biol. Interact. 1992, 81, 1-18
93. Hatch, F. T.; Colvin, M. E. Quantitative Structure-Activity (QSAR) Relationships of Mutagenic Aromatic and Heterocyclic Amines Mutat. Res. 1997, 376, 87-96
94. Bentzien, J.; Hickey, E. R.; Kemper, R. A.; Brewer, M. L.; Dyekjaer, J. D.; East, S. P.; Whittaker, M. An in Silico Method for Predicting Ames Activities of Primary Aromatic Amines by Calculating the Stabilities of Nitrenium Ions J. Chem. Inf. Model. 2010, 50, 274-297
95. Benigni, R.; Passerini, L. Carcinogenicity of the Aromatic Amines: From Structure-Activity Relationships to Mechanisms of Action and Risk Assessment Mutat. Res. 2002, 511, 191-206
96. Benigni, R.; Bossa, C.; Netzeva, T.; Rodomonte, A.; Tsakovska, I. Mechanistic QSAR of Aromatic Amines: New Models for Discriminating between Homocyclic Mutagens and Nonmutagens, and Validation of Models for Carcinogens Environ. Mol. Mutagen. 2007, 48, 754-71
97. Benfenati, E.; Benigni, R.; Demarini, D. M.; Helma, C.; Kirkland, D.; Martin, T. M.; Mazzatorta, P.; Ouedraogo-Arras, G.; Richard, A. M.; Schilter, B.; Schoonen, W. G. E. J.; Snyder, R. D.; Yang, C. Predictive Models for Carcinogenicity and Mutagenicity: Frameworks, State-of-the-Art, and Perspectives J. Environ. Sci. Health, Part C: Environ. Carcinog. Ecotoxicol. Rev. 2009, 27, 57-90
98. Sobol, Z.; Engel, M. E.; Rubitski, E.; Ku, W. W.; Aubrecht, J.; Schiestl, R. H. Genotoxicity Profiles of Common Alkyl Halides and Esters with Alkylating Activity Mutat. Res. 2007, 633, 80-94
99. Eder, E.; Neudecker, T.; Lutz, D.; Henschler, D. Correlation of Alkylating and Mutagenic Activities of Allyl and Allylic Compounds: Standard Alkylation Test vs. Kinetic Investigation Chem. Biol. Interact. 1982, 38, 303-315
100. Ashby, J. The Evaluation of Volatile Chemicals for Mutagenicity Mutagenesis 1989, 4, 160-162
101. Simmon, V. F.. Applications of the Salmonella/Microsome Assay. In Short-Term Tests for Chemical Carcinogens; Stich, H. F.; San, R. H. C., Eds.; Springer-Verlag: New York, 1981; pp 120 - 126.
102. Vinyl chloride (WHO Food Additives Series 19); http://www.inchem.org/ documents/jecfa/jecmono/v19je16.htm.
103. Bolt, H. M. Metabolism of Genotoxic Agents: Halogenated Compounds IARC Sci. Publ. 1984, 63-71
104. Rombach, E. M.; Hanzlik, R. P. Detection of Adducts of Bromobenzene 3,4-Oxide with Rat Liver Microsomal Protein Sulfhydryl Groups Using Specific Antibodies Chem. Res. Toxicol. 1999, 12, 159-163
105. ATSDR Toxicological Profile for Chloroethane; http://www.atsdr.cdc.gov/ toxprofiles/tp105.pdf.
106. Holder, J. W. Analysis of Chloroethane Toxicity and Carcinogenicity Including a Comparison with Bromoethane Toxicol. Ind. Health 2008, 24, 655-675
107. Gargas, M. L.; Sweeney, L. M.; Himmelstein, M. W.; Pottenger, L. H.; Bus, J. S.; Holder, J. W. Physiologically Based Pharmacokinetic Modeling of Chloroethane Disposition in Mice, Rats, and Women Toxicol. Sci. 2008, 104, 54-66
108. Dipple, A.; Levy, L. S.; Lawley, P. D. Comparative Carcinogenicity of Alkylating Agents: Comparisons of a Series of Alkyl and Aralkyl Bromides of Differing Chemical Reactivities As Inducers of Sarcoma at the Site of a Single Injection in the Rat Carcinogenesis 1981, 2, 103-107
109. O'Brien, P. J.; Siraki, A. G.; Shangari, N. Aldehyde Sources, Metabolism, Molecular Toxicity Mechanisms, and Possible Effects on Human Health Crit. Rev. Toxicol. 2005, 35, 609-662
110. Arican, R. Y.; Sahin, Z.; Ustunel, I.; Sarikcioglu, L.; Ozdem, S.; Oguz, N. Effects of Formaldehyde Inhalation on the Junctional Proteins of Nasal Respiratory Mucosa of Rats Exp. Toxicol. Pathol. 2009, 61, 297-305
111. Morris, J. B. Dosimetry, toxicity and carcinogenicity of inspired acetaldehyde in the rat Mutat. Res. 1997, 380, 113-124
112. Dhareshwar, S. S.; Stella, V. J. Your Prodrug Releases Formaldehyde: Should You Be Concerned? No! J. Pharm. Sci. 2008, 97, 4184-4193
113. Collins, J. J.; Acquavella, J. F.; Esmen, N. A. An Updated Meta-Analysis of Formaldehyde Exposure and Upper Respiratory Tract Cancers J. Occup. Environ. Med. 1997, 39, 639-651
114. Arts, J. H.; Rennen, M. A.; de Heer, C. Inhaled Formaldehyde: Evaluation of Sensory Irritation in Relation to Carcinogenicity Regul. Toxicol. Pharmacol. 2006, 44, 144-160
115. Restani, P.; Galli, C. L. Oral Toxicity of Formaldehyde and Its Derivatives Crit. Rev. Toxicol. 1991, 21, 315-328
116. Amberg, A.; Rosner, E.; Dekant, W. Toxicokinetics of methyl tert-butyl ether and its metabolites in humans after oral exposure Toxicol Sci. 2001, 61, 62-67
117. Petkovska, R.; Cornett, C.; Dimitrovska, A. Development and Validation of Rapid Resolution RP-HPLC Method for Simultaneous Determination of Atorvastatin and Related Compounds by Use of Chemometrics Anal. Lett. 2008, 41, 992-1009
118. Hurley, T. R.; Colson, C. E.; Clipper, S. A.; Uhlendorf, S. E.; Reily, M. D. Photodecomposition of CI-981, an HMG-CoA Reductase Inhibitor Tetrahedron 1993, 49, 1979-1984
119. Mutual Recognition Procedure IS/H/100-102/01-03/MR; http://www.hma.eu/ fileadmin/dateien/Human-Medicines/CMD-h-/cmdh-pressreleases/2007-03.pdf.
120. Impurities in new Drug Substances. ICH Topic Q3A (R2): http://www.ema.europa.eu/pdfs/human/ich/273799en.pdf.
121. Arf Mice; http://ntp.niehs.nih.gov/files/gmm13-web1.pdf, 2007.
122. Mesityl Oxide. Hazard Assessment by U.S. Environmental Protection Agency. http://www.epa.gov/opprd001/inerts/mesityl.pdf.
123. Robinson, D. I.. Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A Review and Perspective. Org Process Res Dev. 2010. DOI: 10.1021/op900341a.
124. Gocke, E.; Mullera, L. In Vivo Studies in the Mouse to Define a Threshold for the Genotoxicity of EMS and ENU Mutat. Res. 2009, 678, 101-107
125. Adams, T. B.; Gavin, C. L.; Taylor, S. V.; Waddell, W. J.; Cohen, S. M.; Feron, V. J.; Goodman, J.; Rietjens, I. M. C. M.; Marnett, L. J.; Portoghese, P. S.; Smith, R. L. The FEMA GRAS Assessment of α,β-Unsaturated Aldehydes and Related Substances Used As Flavor Ingredients Food Chem. Toxicol. 2008, 46, 2935-2967
126. IPCS, WHO Food Additive Series 40; Saturated aliphatic acyclic linear primary alcohols, aldehydes and acids. http://www.inchem.org/documents/jecfa/ jecmono/v040je10.htm.
127. IPCS, EHC 64; Carbamate pesticides: a general introduction. http://www.inchem.org/documents/ehc/ehc/ehc64.htm.
128. Lee, C.; Helmy, R.; Strulson, C.; Plewa, J.; Kolodziej, E.; Antonucci, V.; Mao, B.; Welch, C. J.; Ge, Z.; Al-Sayah, M. A.. Removal of Electrophilic Potential Genotoxic Impurities Using Nucleophilic Reactive Resins. Org. Process Res. Dev. 2010. DOI: 10.1021/op1000397.
129. Zeiger, E.; Anderson, B.; Haworth, S.; Lawlor, T.; Mortelmans, K. Salmonella Mutagenicity Tests: IV. Results from the Testing of 300 Chemicals Environ. Mol. Mutagen. 1988, 11 (Suppl. 12) 1-157
130. IUCLID Data Set for Benzoyl Chloride; http://www.epa.gov/chemrtk/pubs/ summaries/benzchlr/c14969.pdf.
131. Acute exposure guideline level for chloroacetyl chloride; http://www.epa.gov/oppt/aegl/pubs/chloroacetylchloride-and- dichloroacetylchloride-tsd-interimversion1-8-28-07.pdf.
132. BASF Safety Data Sheet for Ethyl Chloroformate; http://worldaccount.basf. com/wa/PublicMSDS/PDF/09007af88009b79d.pdf.
133. Chloromethane, CICAD 28; http://www.inchem.org/documents/cicads/cicads/ cicad28.htm.
134. Organisation for Economic Co-operation and Development (OECD) Screening Information Data Sets (SIDS); Chloromethane. http://www.chem.unep.ch/irptc/sids/ OECDSIDS/CLMETHANE.pdf.
135. Chloromethane, EPA IRIS; http://www.epa.gov/iris/subst/1003.htm.
136. ATSDR Toxicological Profile for Chloromethane; http://www.atsdr.cdc.gov/ toxprofiles/tp106.html.
137. Environment Canada Screening Assessment Report for Chloromethane; http://www.ec.gc.ca/substances/ese/eng/challenge/batch6/batch6-74-87-3.cfm.
138. Chloroethane, EPA IRIS; http://www.epa.gov/iris/subst/0523.htm.
139. Chloroethane: Proposition 65 Safe Harbor Levels Development; Office of Environmental Health Hazard Assessment (OEHHA) of the California Environmental Protection Agency: Sacramento, CA, 2009; p 3; http://oehha.ca.gov/prop65/pdf/ 2009FebruaryStat.pdf.
140. 1-Chlorobutane: Organisation for Economic Co-operation and Development (OECD) Screening Information Data Sets (SIDS); http://www.inchem.org/documents/ sids/sids/109693.pdf.
141. Organisation for Economic Co-operation and Development (OECD) Screening Information Data Sets (SIDS); Benzyl chloride. http://www.chem.unep.ch/irptc/ sids/OECDSIDS/100447.pdf.
142. Benzyl chloride: Proposition 65 Safe Harbor Levels Development; Office of Environmental Health Hazard Assessment (OEHHA) of the California Environmental Protection Agency: Sacramento, CA, 2009; p 3; http://oehha.ca.gov/prop65/pdf/ 2009FebruaryStat.pdf.
143. Environment Canada Screening Assessment Report for Benzyl Chloride; http://www.ec.gc.ca/substances/ese/eng/challenge/batch6/batch6-100-44-7-en.pdf.
144. Bromomethane, IPCS EHC166; http://www.inchem.org/documents/ehc/ehc/ ehc166.htm.
145. Organisation for Economic Co-operation and Development (OECD) Screening Information Data Sets (SIDS); Bromomethane. http://www.chem.unep.ch/irptc/sids/ OECDSIDS/Methyl%20bromide.pdf.
146. Bromomethane, EPA IRIS; http://www.epa.gov/iris/subst/0015.htm.
147. ATSDR Toxicological Profile for Bromomethane: http://www.atsdr.cdc.gov/ toxprofiles/tp27.pdf.
148. Bromoethane CICAD 42; http://whqlibdoc.who.int/HQ/2002/a75356.pdf.
149. 1-Bromopropane, NTP Review; http://ntp.niehs.nih.gov/index.cfm?objectid= 4E0C03A9-F1F6-975E-79F1E370B9027815.
150. Carcinogenic Potency Database: Formaldehyde; http://potency.berkeley.edu/ chempages/formaldehyde.html.
151. EPA IRIS Reference Dose for Formaldehyde; http://www.epa.gov/iris/subst/ 0419.htm.
152. Concise International Chemical Assessment Document 40: Formaldehyde; http://www.inchem.org/documents/cicads/cicads/cicad40.htm.
153. Evaluation Report of Food Additives: Acetaldehyde; http://www.fsc.go.jp/ english/evaluationreports/foodadditive/acetaldehyde-report.pdf.
154. Carcinogenic Potency Database: Acetaldehyde; http://potency.berkeley.edu/ chempages/acetaldehyde.html.
155. EPA IRIS Reference Dose for Formaldehyde; http://www.epa.gov/IRIS/subst/ 0290.htm.
156. Carcinogenic Potency Database: Benzaldehyde; http://potency.berkeley.edu/ chempages/benzaldehyde.html.
157. EPA IRIS Reference Dose for Benzaldehyde; http://www.epa.gov/iris/subst/ 0332.htm.
158. Carcinogenic Potency Database: Acrolein; http://potency.berkeley.edu/ chempages/acrolein.html.
159. Concise International Chemical Assessment Document 43: Acrolein; http://www.inchem.org/documents/cicads/cicads/cicad43.htm.
160. EPA IRIS Reference Dose for Acrolein; http://www.epa.gov/ncea/iris/subst/ 0364.htm.
161. Carcinogenic Potency Database: Crotonaldehyde; http://potency.berkeley. edu/chempages/crotonaldehyde.html.
162. Concise International Chemical Assessment Document 74: 2-Butenal; http://libdoc.who.int/publications/2008/9789241530743-eng.pdf.
163. Carcinogenic Potency Database: Cinnamaldehyde; http://potency.berkeley. edu/chempages/trans-cinnamaldehyde.html.